Biosimilars

Capping the price of reference drugs 'is detrimental' to biosimilars and generics, says the EGA

EGA: let originators charge more in Spain… to boost biosimilars

By Fiona BARRY

The European Generic and Biosimilar Medicines Association (EGA) and the Spanish Generic Medicines Association (AESEG) today revealed plans to remove market barriers to biosimilars and small molecule generics and create thousands of jobs.

Coming to America? Novartis subsidiary launches first biosimilar product in the US

Update - Wholesale cost of Zarxio will be 15% less than Amgen's Neupogen

Biosimilars land in the US as Sandoz launches Zarxio

By Dan Stanton

Sandoz has launched Zarxio, the first biosimilar in the US, despite a last ditch effort to block the copycat version of Neupogen by Amgen.